Sign In
Buy ZYNE
$1.30
+0 (+0%)
At Close: Jan 09, 2024
Zynerba Pharmaceuticals showcases Zygel study poster at annual SLEEP meeting
01:47pm, Friday, 11'th Jun 2021
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) unveiled a poster highlighting sleep data from a study of its Zygel transdermal cannabinoid therapy at the Associated Professional Sleep Societies, SLEEP 2021
DEVON, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare
Smoked! How the Hottest Cannabis Stocks Fared This Week
09:55am, Friday, 11'th Jun 2021
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continue
Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting
04:05pm, Wednesday, 09'th Jun 2021
– 46.4% of shares voted, quorum not established to hold annual meeting –
Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
07:30am, Friday, 04'th Jun 2021
DEVON, Pa., June 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare
DEVON, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare
Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
07:30am, Thursday, 27'th May 2021
DEVON, Pa., May 27, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n
Here Are the Cannabis Stocks That Caught Fire This Week
08:19am, Friday, 14'th May 2021
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continue
Zynerba's CBD skin gel Zygel offers a potential goldmine of therapies for Fragile X syndrome and other conditions
06:30am, Thursday, 13'th May 2021
Developing novel transdermal CBD treatments to treat patients suffering rare epilepsies and neurological disorders Lead development candidate Zygel offers a potential goldmine of therapies for multipl
Zynerba's Shares Jump on CBD Zygel Trial Plans, Company Reports Cash Until 2024
02:12pm, Wednesday, 12'th May 2021
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) disclosed Wednesday its first-quarter net loss of $8.0 million or a loss of 20 cents per share, compared to $12.34 million in the same period of 2020 or a l
These Reddit Penny Stocks Are Soaring Today, Are They Worth Buying?
01:31pm, Wednesday, 12'th May 2021
These Reddit penny stocks are climbing today; are they worth adding to your watchlist? The post These Reddit Penny Stocks Are Soaring Today, Are They Worth Buying?
Zynerba says its fully funded well into 2024; lays out plans for Zygel RECONNECT trial for Fragile X patients
09:54am, Wednesday, 12'th May 2021
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) (FRA:6ZY) told investors it believes it has sufficient cash to fund its operations well into the first half of 2024 after the company reported cash and equiva
Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights
06:45am, Wednesday, 12'th May 2021
– RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, expected to be initiated in the third quarter of 2021 –
Zynerba receives FDA guidance on confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome
04:47pm, Wednesday, 05'th May 2021
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has received guidance from the US Food and Drug Administration (FDA) on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS). The
Zynerba presents two posters on Zygel at the Society of Biological Psychiatry 2021 Virtual Meeting
03:21pm, Thursday, 29'th Apr 2021
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the
